Company: BIAF
Filing Date: 2025-06-27
Form Type: POS AM
Source: 0001641172-25-016927
Chunk: 200

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-06-27
Form: POS AM
Chunk 200
---
 |     |      | (8,592,189 | ) |
| Cash and cash equivalents                                                                                             
 at beginning of year                                                                                                  |     |      |  2,821,570 |   |     |      | 11,413,759 |   |
| Cash                                                                                                                  
 and cash equivalents at end of year                                                                                   |     | $    |  1,105,291 |   |     | $    |  2,821,570 |   |
| Supplemental disclosures                                                                                              
 of cash flow information:                                                                                             |     |      |            |   |     |      |            |   |
| Income taxes paid                                                                                                     
 in cash                                                                                                               |     | $    |     11,650 |   |     | $    |     20,993 |   |
| Interest paid                                                                                                         |     |      |     17,610 |   |     |      |     37,125 |   |
| Interest expense paid in cash                                                                                         |     |      |     17,610 |   |     |      |     37,125 |   |
| Noncash investing activities:                                                                                         |     |      |            |   |     |      |            |   |
| Stock issuance in                                                                                                     
 connection with the acquisition                                                                                       |     | $    |          — |   |     | $    |  1,000,000 |   |
| Noncash financing activities:                                                                                         |     |      |            |   |     |      |            |   |
| Fair value of warrants                                                                                                
 issued to placement agents                                                                                            |     | $    |     74,281 |   |     |      |          — |   |

<div align='center'>The accompanying notes are an integral part of these consolidated financial statements.</div>

| F-19 |

bioAffinity Technologies, Inc.

Notes to Consolidated Financial Statements

For the Years Ended December 31, 2024 and 2023

Note 1. BASIS OF PRESENTATION, ORGANIZATION AND NATURE OF OPERATIONS

NATURE OF OPERATIONS, ORGANIZATION, AND BASIS OF PRESENTATION

Description of Business

bioAffinity Technologies, Inc., a Delaware corporation (the “Company,” or “bioAffinity Technologies”), addresses the need for noninvasive diagnosis of lung cancer at early stage and other diseases of the lung. bioAffinity Technologies’ proprietary platform uses flow cytometry and automated data analysis built by machine